Gabriela Denning, Ph.D

Vice President of Research & Development

Dr. Denning received her Ph.D. in Biochemistry from The University of Texas Medical Branch. Her post-doctoral studies at The Scripps Research Institute under Dr. Peter K. Vogt, focused on understanding novel mechanisms of PTEN tumor suppressor function. Currently, Dr. Denning oversees all pre-clinical research and development efforts at Expression Therapeutics. Dr. Denning oversees many company roles including directing the development and execution of NIH STTR and SBIR funded programs in lentiviral and adeno-associated viral gene therapy of hemophilia A as well as recombinant ET3i immune tolerance induction for FVIII inhibitors.

Roles at Expression Therapeutics

  • Vice President of Research & Development

    Current role

My work style

How I prefer to work

Qualities I value in my colleagues

Sign up to see more about the team at Expression Therapeutics

My pet peeves

My communication style

Org chart

Direct reports

No reports


No teams